Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Invega Trinza

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

Novartis’ acromegaly therapy cleared by FDA

Signifor LAR shows superior efficiency to older treatments

- PMLiVE

Cyramza gets FDA green light in lung cancer

Drug steadily being approved for further uses

- PMLiVE

Biosimilar Remicade reaches market in Japan and India

Nippon Kayaku’s version of arthritis drug was approved in July

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

FDA approves Baxter drug for rare form of haemophilia

Obizur is derived from pig proteins

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

Olysio drives J&J pharma sales

But hepatitis C drug set to face serious competition from Gilead Sciences

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links